XSHG600998
Market cap3.38bUSD
Jan 08, Last price
4.91CNY
1D
-1.01%
1Q
-10.24%
Jan 2017
-50.60%
IPO
-41.41%
Name
Jointown Pharmaceutical Group Co Ltd
Chart & Performance
Profile
Jointown Pharmaceutical Group Co., Ltd provides marketing, distribution, and logistics services for digital pharmaceutical businesses. It wholesales Chinese herbal medicines, Chinese patent medicines, chemical medicinal materials, chemical medicine preparations, antibiotic preparations, biochemical drugs, biological products, chemical raw materials, and medical toxic drugs. The company was founded in 1999 and is based in Wuhan, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | 150,139,847 6.92% | 140,424,192 14.72% | |||||||
Cost of revenue | 141,529,508 | 134,608,978 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | 8,610,339 | 5,815,213 | |||||||
NOPBT Margin | 5.73% | 4.14% | |||||||
Operating Taxes | 701,202 | 552,554 | |||||||
Tax Rate | 8.14% | 9.50% | |||||||
NOPAT | 7,909,137 | 5,262,659 | |||||||
Net income | 2,174,043 4.27% | 2,084,963 -14.84% | |||||||
Dividends | (936,935) | (548,621) | |||||||
Dividend yield | 3.42% | 2.16% | |||||||
Proceeds from repurchase of equity | (2,000,000) | ||||||||
BB yield | 7.30% | ||||||||
Debt | |||||||||
Debt current | 10,121,827 | 12,025,505 | |||||||
Long-term debt | 2,678,058 | 3,371,753 | |||||||
Deferred revenue | 244,454 | 231,808 | |||||||
Other long-term liabilities | 360,700 | 74,677 | |||||||
Net debt | (7,791,386) | (5,135,557) | |||||||
Cash flow | |||||||||
Cash from operating activities | 4,782,207 | 3,986,228 | |||||||
CAPEX | (1,048,815) | ||||||||
Cash from investing activities | (1,361,130) | 1,487,695 | |||||||
Cash from financing activities | (2,236,976) | ||||||||
FCF | 9,187,420 | 6,533,980 | |||||||
Balance | |||||||||
Cash | 17,039,212 | 17,495,685 | |||||||
Long term investments | 3,552,059 | 3,037,130 | |||||||
Excess cash | 13,084,279 | 13,511,606 | |||||||
Stockholders' equity | 22,098,097 | 20,892,295 | |||||||
Invested Capital | 29,382,319 | 30,132,949 | |||||||
ROIC | 26.58% | 17.00% | |||||||
ROCE | 20.10% | 13.20% | |||||||
EV | |||||||||
Common stock shares outstanding | 3,908,892 | 4,064,708 | |||||||
Price | 7.01 12.16% | 6.25 -11.47% | |||||||
Market cap | 27,401,330 7.86% | 25,404,428 -7.94% | |||||||
EV | 25,103,771 | 26,297,006 | |||||||
EBITDA | 9,385,284 | 6,551,496 | |||||||
EV/EBITDA | 2.67 | 4.01 | |||||||
Interest | 1,317,638 | 1,221,466 | |||||||
Interest/NOPBT | 15.30% | 21.00% |